Core Viewpoint - The innovative drug sector is experiencing significant growth, with multiple companies seeing substantial stock price increases, indicating a bullish trend in the market [1]. Group 1: Stock Performance - Shuyatain's stock price increased by 14.66%, reaching 26.52 [2] - Other notable performers include Dizhe Pharmaceutical with a 10.70% increase, Baili Tianheng at 10.63%, and Huana Pharmaceutical at 10.33% [2] - In the Hong Kong market, Keystone Pharmaceuticals surged over 18%, while CSPC Pharmaceutical and Xiansheng Pharmaceutical rose by over 12% and 8%, respectively [3] Group 2: Market Trends - The overall trend in the innovative drug sector shows a strong upward movement, with several companies hitting their daily price limits [1] - The performance of stocks in both mainland and Hong Kong markets reflects a growing investor confidence in the pharmaceutical industry [3]

截至本公告披露日，BAT2506（戈利木单抗注射液）已获得欧洲 EMA 批准 上市，欧洲注册商品名为 Gotenfia®；已向中国 NMPA、美国 FDA、巴西 ANVISA 等药监机构提交上市申请，目前正在评审中。 协议履行的风险详见公司于 2024 年 5 月 29 日披露的《百奥泰生物制药股份 有限公司关于与 STADA 就 BAT2506（戈利木单抗）注射液签署授权许可与商业 化协议的公告》（公告编号：2024-031）之"五、协议履行的风险分析"。 敬请广大投资者注意投资风险，公司将严格按照有关规定及时对协议后续进 展情况履行信息披露义务。 特此公告。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 百奥泰生物制药股份有限公司（以下简称"百奥泰"或"公司"）于 2024 年 5 月 27 日召开公司第二届董事会第十六次会议，审议通过了《关于就 BAT2506（戈 利木单抗）签署授权许可与商业化协议的议案》，并于 2024 年 5 月 28 日与 STADA Arzneimittel AG（以下简称"STADA"） ...

Investment Rating - The report does not explicitly state an investment rating for the industry, but it suggests a focus on companies with validated platforms and effective innovative drugs, indicating a positive outlook for certain segments within the industry [2]. Core Insights - The pharmaceutical and biotechnology sectors are experiencing a shift towards a multi-layered overseas strategy, with Chinese companies increasingly recognized by global multinational corporations (MNCs) for their research capabilities and technology platforms [2]. - Recent significant business development (BD) deals include China National Pharmaceutical Group's exclusive licensing agreement for the drug Rovabatinib worth $1.53 billion and the collaboration between Deqi Pharmaceutical and UCB for the CD19/CD3 bispecific T cell engager ATG-201, valued at over $1.18 billion [2][10]. - The report highlights the performance of the in vitro diagnostics sector, which was the only sub-sector to see a gain of 0.18%, while other segments like medical device and vaccine sectors faced declines [7][8]. Market Weekly Review - The pharmaceutical and biotechnology sector fell by 2.78% from March 2 to March 6, underperforming the Wind All A index (-2.3%) and the CSI 300 index (-1.07%) [7]. - Notable stock performances included Yahui Pharmaceutical (+38.1%), Zhejiang Pharmaceutical (+12.8%), and Zhongyuan Xiehe (+12.7%) as top gainers, while Tianzhihang-U (-14.8%), Furui Medical (-13.1%), and Haoyuan Pharmaceutical (-12.3%) were the biggest losers [10]. Industry News and Key Company Announcements - On March 6, Xianweida Biopharmaceutical and Pfizer announced the approval of a new indication for their GLP-1 receptor agonist, Enoglutide, for long-term weight management in adults [10]. - China National Pharmaceutical Group's licensing agreement for Rovabatinib includes a $135 million upfront payment and potential milestone payments based on sales performance [10]. - Deqi Pharmaceutical's agreement with UCB for ATG-201 includes an upfront payment of $80 million and potential milestone payments exceeding $1.1 billion [10]. - Wanbangde reported a significant increase in net profit for Q1 2026, reaching 165 million yuan, a year-on-year growth of 985.4% [11].

证券代码： 688177 证券简称：百奥泰 公告编号：2026-014 百奥泰生物制药股份有限公司 自愿披露关于 BAT8008 联合 BAT1006 及曲妥珠 单抗治疗晚期实体瘤获得药物临床试验批准通 知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 百奥泰生物制药股份有限公司（以下简称"百奥泰"或"公司"）于近日收到国 家药品监督管理局（以下简称"国家药监局"）核准签发的《药物临床试验批准通 知书》，公司在研药品 BAT8008 联合 BAT1006 及曲妥珠单抗用于治疗 HER2 阳 性晚期实体瘤的临床试验申请获得批准。 考虑到临床研究周期长、投入大，过程中不可预测因素较多，临床试验、审 评和审批的结果以及时间都具有一定的不确定性，容易受到一些不确定性因素的 影响，敬请广大投资者谨慎决策，注意防范投资风险。现将相关情况公告如下： 一、 《药物临床试验批准通知书》基本情况 1、BAT8008 药品名称：注射用 BAT8008 剂型：注射剂 规格：100mg/瓶 审批结论：根据《中华人民共和国药 ...

Investment Rating - The overall industry rating is neutral, indicating that the expected return over the next six months is between -5% and 5% relative to the CSI 300 index [8]. Core Insights - The pharmaceutical sector experienced a decline of 2.67% on March 3, 2025, underperforming the CSI 300 index by 1.13 percentage points, ranking 14th among 31 sub-industries in the Shenwan classification [4]. - Notable performances within sub-industries included offline pharmacies (-0.62%), blood products (-1.37%), and in vitro diagnostics (-1.50%), while hospitals (-4.32%), medical R&D outsourcing (-3.53%), and other biological products (-3.39%) lagged behind [4]. - Key individual stock performances included Kanghui Co., Ltd. (+10.01%), Lianhuan Pharmaceutical (+3.89%), and Jiuan Medical (+3.42%) on the gainers' list, while Tianzhihang (-11.45%), Saike Xide (-11.06%), and Wanze Co., Ltd. (-10.01%) were among the biggest losers [4]. Sub-industry Ratings - Chemical pharmaceuticals: No rating - Traditional Chinese medicine production: No rating - Biopharmaceuticals II: Neutral - Other pharmaceuticals: Neutral [3]. Industry News - Eli Lilly's Lebrikizumab, an anti-IL-13 monoclonal antibody, has received acceptance for market application in China, having previously been approved by the FDA in the U.S. for moderate to severe atopic dermatitis [5]. - Yihong Pharmaceutical's APL-1702 has been approved for the treatment of confirmed CIN2 patients aged 18 and above [5]. - Baiyao's Usymro has received approval from the UK Medicines and Healthcare products Regulatory Agency, enhancing the company's international presence [5]. - Yiling Pharmaceutical's chemical raw material drug, Pomalidomide, has been approved for market application [6]. - Haichuang Pharmaceutical's HP515, a selective THR-β agonist for treating metabolic-associated fatty liver disease, has completed participant enrollment in its Phase IIa clinical trial [6].

证券代码： 688177 证券简称： 百奥泰 公告编号：2026-013 百奥泰生物制药股份有限公司 自愿披露关于 Usymro ®（乌司奴单抗注射液）获 得英国 MHRA 上市批准的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 百奥泰生物制药股份有限公司（以下简称"百奥泰"或"公司"）于近日收到 了英国药品和健康产品管理局（以下简称"英国MHRA"）签发的关于Usymro ® （BAT2206，乌司奴单抗注射液）上市批准通知。 现将相关情况公告如下： 一、 药品相关情况 （一） 药品名称：乌司奴单抗注射液 皮下注射液：45 mg/瓶（西林瓶）、 45 mg/支（PFS）、90 mg/支（PFS）； 静脉注射液：130 mg/瓶 （四） 成人适应症：中重度斑块状银屑病（PsO），活动性银屑病关节炎 （PsA），中重度活动性克罗恩病（CD）；儿童适应症：中重度斑块状银屑病 （PsO），中重度活动性克罗恩病（CD） 二、 药品其他相关情况 BAT2206 是百奥泰根据中国 NMPA、美国 FDA、欧洲 EMA 生物类似 ...

Core Viewpoint - The company Baiotai has completed clinical trials for the subcutaneous formulation of tocilizumab and is actively preparing for the submission of applications both domestically and for overseas authorization [1] Group 1 - The subcutaneous formulation of tocilizumab has completed clinical trials [1] - Baiotai is currently working on preparations for application submissions [1]

Core Viewpoint - The company Baiotai has completed clinical trials for its subcutaneous formulation of Tocilizumab and is actively preparing for the submission of relevant applications [2] Group 1 - The subcutaneous formulation of Tocilizumab has successfully completed clinical trials [2] - The company is currently advancing preparations for application submission [2]

Core Viewpoint - The company emphasizes the uncertainty in the drug approval process and is committed to advancing its applications while ensuring timely information disclosure to investors [2]. Group 1: Company Operations - The company has established a robust talent pipeline and continues to attract top talent, which supports stable operations in research and innovation [2]. - The company remains focused on its core business and is actively advancing its research and commercialization efforts [2]. Group 2: Future Outlook - The introduction of more products is expected to gradually improve and enhance the company's operational performance [2].

Core Viewpoint - The company, Baiotai, announced its financial performance for 2025, indicating a significant increase in revenue while still reporting a net loss, although the loss has decreased compared to the previous year [2] Financial Performance - The company expects to achieve an operating revenue of 933.685 million yuan in 2025, representing a year-on-year growth of 25.64% [2] - The net profit attributable to the parent company is projected to be -336.4409 million yuan, which reflects a reduction in loss by 173.8629 million yuan compared to the same period last year [2] - The basic earnings per share are estimated at -0.81 yuan, with a weighted average return on net assets of -62.32% [2]